Challenges in developing endpoints for type 1 diabetes intervention studies
Authors:
- 21 September 2009
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 25 (8) , 694-704
Abstract
Development of efficient and safe intervention strategies for preserving and/or restoring endogenous insulin production in type 1 diabetes has encountered a wide range of challenges, including lack of standardized trial protocols and of consensus on appropriate efficacy endpoints. For the greatest part, difficulties resided in choosing the most suitable assay(s) and parameter(s) to assess the β‐cell function. It is now an accepted approach to evaluate endogenous insulin secretion by measuring C‐peptide levels (with highly sensitive and normalized measurement methods) in response to a physiologic stimulus (liquid mixed‐meal) under standardized conditions. Preventive interventions mandate the identification of well‐defined, reliable and validated mechanistic or immunological markers of efficacy that would correlate with (and predict) the clinical outcome. This has not been consistently achieved to date. However, it has been generally agreed that for preventive studies performed very early in the disease course (in subjects without signs of autoimmunity against β‐cells) development of two or more islet related autoantibodies could be employed as biomarkers of disease and thereafter, diagnostic criteria of diabetes serve as suitable endpoints. This report summarizes the conclusions of the D‐Cure workshop of international experts held in Barcelona in April 2007 and the current recommendations and updates in the field. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 70 references indexed in Scilit:
- Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 yearsClinical Immunology, 2009
- Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1Diabetes Care, 2008
- GAD Treatment and Insulin Secretion in Recent-Onset Type 1 DiabetesNew England Journal of Medicine, 2008
- Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 DiabetesDiabetes Care, 2008
- Autoantibodies in type 1 diabetesAutoimmunity, 2008
- A Two Year Observational Study of Nicotinamide and Intensive Insulin Therapy in Patients with Recent Onset Type I Diabetes MellitusJournal of Pediatric Endocrinology and Metabolism, 2005
- Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus - a new surrogate measure of non-progression?Pediatric Diabetes, 2004
- Increased insulin secretion in puberty: A compensatory response to reductions in insulin sensitivityThe Journal of Pediatrics, 1989
- A Randomized Trial of Intensive Insulin Therapy in Newly Diagnosed Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1989
- Abnormal Patterns of Insulin Secretion in Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1988